ClinicaliQ Trial Snapshot
- The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke — Recruiting • Cardiology / Cardiovascular • NCT05636748.
- What is being tested: This trial investigates the origin of thrombi causing ischaemic stroke and examines whether thrombosis itself is the primary pathogenic mechanism, addressing the current difficulty in identifying thrombus sources and confirming their role in stroke aetiology.
- Patient eligibility overview: The trial includes patients with ischaemic stroke where thrombus is suspected or confirmed as the causative mechanism, though specific inclusion/exclusion criteria require full protocol review for precise eligibility parameters.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Ischaemic stroke is usually due to occlusion of a cerebral artery by thrombus. However, it is often difficult to identify the source of thrombus, or to confirm thrombus as a cause of ischaemic stroke. Moreover, it is debated whether thrombosis plays any role in certain types of stroke such as lacunar stroke. In preliminary studies, the investigators have evaluated a novel clinical grade thrombus-specific radiotracer, 18F-GP1, which has a high specificity for the glycoprotein IIb/IIIa receptor on activated platelets. The investigations have demonstrated that 18F-GP1 is highly sensitive to in…
Eligibility Snapshot
- : * Males and females ≥18 years old * Diagnoses of acute ischaemic stroke (within 21 days of symptom onset) as per American Heart and Stroke Association guidelines
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.